Among 125 HER2+ breast cancer patients, patients receiving NAC again had significantly shorter DFS (p=0.006, log-rank test, Figure 2E), while there was no relationship with OS (p=0.503, log-rank test, Figure 2F). This evidence concerns the gene ERBB2 and breast carcinoma.